OUR LAB
Full control. Fast innovation. True Ownership
At Quimatryx, we operate a fully equipped 150m² research laboratory dedicated to the design and synthesis of novel small molecules targeting epigenetic mechanisms.
Owning our discovery platform gives us full control over the R&D process—from initial conception to optimized drug candidate.
This in-house capability allows us to accelerate innovation, maintain independence, and safeguard our intellectual property at every stage.
Our approach is grounded on rational medicinal chemistry, not random screening. We design and synthesize new families of selective HDAC6 inhibitors based on deep mechanistic insights and structural knowledge.
With direct access to early screening and structural characterization, we fast-track key decision points. Our robust infrastructure enables for parallel exploration of multiple compound series, reducing development risk and maximizing opportunity.
All of this is powered by a highly skilled scientific team with proven expertise in epigenetics, medicinal chemistry, and drug development.
At Quimatryx, owning discovery means shaping the future of epigenetic therapies.
A NEW ERA OF EPIGENETIC THERAPIES
We are advancing a new generation of highly selective HDAC6 inhibitors, designed to unlock the full therapeutic potential of precision epigenetics in oncology, autoimmune, and neurological disorders.
KEY STRENGTHS OF OUR HDAC6 INHIBITOR PLATFORM
1. Targeting the Epigenetic Root Cause: Our inhibitors selectively target HDAC6, a key regulator of cytoplasmatic proteins involved in cancer progression, immune dysfunction, and neurological disorders, among others. Unlike nuclear HDACs, HDAC6 does not alter core epigenetic programming — offering high selectivity and low systemic toxicity.
2. First-in-Class Selectivity and Safety: Our compounds are engineered for highly selective HDAC6 inhibition, minimizing off-target effects common in broad-spectrum HDAC inhibitors.
This translates into superior safety, enhanced tolerability, and potential for long-term treatment.
3. Multi-Disease and Multi-Tissue Impact: HDAC6 is overexpressed tumors cells, immune cells, and neurons.
Our inhibitors offer a unified therapeutic strategy to halt tumor growth and metastasis, recalibrate immune responses in autoimmune diseases, and preserve neuronal function in neurodegenerative disorders, such as ALS, Parkinson’s, Charcot-Marie-Tooth and multiple sclerosis, among others.
4. Fully Integrated Discovery Platform: All our HDAC6 inhibitors are designed, synthesized, and optimized in-house through a fully integrated medicinal chemistry platform.
Full ownership of the discovery process ensures faster development timelines, greater innovation control, and strong IP protection.
5. Synergy with Existing Therapies: HDAC6 inhibition enhances the effect of standard-of-care therapies —including chemotherapy and immunotherapy —while mitigating toxicity. Our candidates are being developed both as monotherapies and in combination regimens.
PIPELINE
Driven by scientific excellence and innovation, our mission is to unlock the full potential of epigenetics to address urgent medical needs in oncology, neurodegeneration, and autoimmune diseases.
We are focused on developing highly selective HDAC6 inhibitors capable of restoring abnormal protein function.
Our pipeline reflects our commitment to next-generation HDAC6 inhibitors with superior efficacy, minimal toxicity, and meaningful patient outcomes.
We welcome you to explore our pipeline and discover how our programs are advancing next-generation therapies.
Discovery
Non-regulatory Preclinic
IND-Enabling
Phase 1
Phase 2
HDAC6 selective inhibitor
QTX125 is an HDAC6 inhibitor currently in phase 1 clinical trials in China for solid tumors and hematologic neoplasms. FIH January 2026. An out-license agreement was signed with HiDiamond for the rights to the compound in Greater China and other territories.
Non-hydroxamic HDAC6 selective inhibitor. BBB-permeable
QTX153 is an HDAC6 inhibitor currently in development for neurodegenerative diseases (ALS, Charcot-Marie-Tooth, Rett) and obesity.
QTX125
First-in-Class Selective HDAC6 Inhibitor for Oncology
QTX125 is a highly selective hydroxamic HDAC6 inhibitor developed for hematological malignancies, such as mantle cell lymphoma, as well as, solid tumors, including pancreatic and lung cancers.
The compound is advancing toward clinical development following successful regulatory preclinical studies.
QTX125 is a first-in-class selective HDAC6 inhibitor designed through proprietary medicinal chemistry at Quimatryx.
High selectivity for HDAC6 over other HDAC isoforms (>50-fold selectivity).
Potent inhibition of HDAC6 enzymatic activity (IC₅₀ = 0.69 nM).
Discovery
Non-regulatory Preclinic
IND-Enabling
Phase 1
Phase 2
HDAC6 selective inhibitor
QTX125 is an HDAC6 inhibitor currently in phase 1 clinical trials in China for solid tumors and hematologic neoplasms. FIH January 2026. An out-license agreement was signed with HiDiamond for the rights to the compound in Greater China and other territories.
Non-hydroxamic HDAC6 selective inhibitor. BBB-permeable
QTX153 is an HDAC6 inhibitor currently in development for neurodegenerative diseases (ALS, Charcot-Marie-Tooth, Rett) and obesity.
QTX125
First-in-Class Selective HDAC6 Inhibitor for Oncology
QTX125 is a highly selective hydroxamic HDAC6 inhibitor developed for hematological malignancies, such as mantle cell lymphoma, as well as, solid tumors, including pancreatic and lung cancers.
The compound is advancing toward clinical development following successful regulatory preclinical studies.
QTX125 is a first-in-class selective HDAC6 inhibitor designed through proprietary medicinal chemistry at Quimatryx.
High selectivity for HDAC6 over other HDAC isoforms (>50-fold selectivity).
Potent inhibition of HDAC6 enzymatic activity (IC₅₀ = 0.69 nM).
QTX125 – EFFICACY IN PRECLINICAL MODELS
QTX125 demonstrates superior inhibition of tumor cell proliferation compared to reference antitumoral compounds, both in solid and hematological tumors.
Complete tumor growth inhibition and regression in models of mantle cell lymphoma and triple hit follicular lymphoma, pancreatic and lung cancer.
Lead indications include non-Hodgkin lymphomas, such as mantle cell lymphoma, DLBCL and follicular lymphoma, as well as solid tumors, like pancreatic and lung cancers.
SAFETY PROFILE
A full preclinical toxicology and pharmacology package have been successfully completed.
A desirable maximum tolerated dose (MTD), no observed adverse effect level (NOAEL), highest non-severely toxic dose (HNSTD) level in rats and dogs.
No significant adverse effects were observed in CNS following administration in rats.
No chromosomal aberrations (in vitro and in vivo), cardiotoxicity (in vitro and in vivo), or respiratory issues (in vivo) were detected. These results support the advancement of QTX125 into clinical development for oncology indications, with a strong foundation of regulatory compliance and safety.
CLINICAL DEVELOPMENT
QTX125, our first-in-class selective HDAC6 inhibitor, has recently entered clinical development.
In 2022, Quimatryx licensed QTX125 to HiDiamond, a biopharmaceutical company based in China, for regulatory development and commercialization in Southeast Asia.
Following the successful completion of regulatory preclinical studies, including pivotal GLP-compliant toxicology, and regulatory approval from the Chinese NMPA (National Medical Products Administration), Phase I clinical trials started in China.
These trials are evaluating the safety, pharmacokinetics, and preliminary efficacy of QTX125 in patients with advanced solid tumors and hematological malignancies.
Quimatryx retains all rights to QTX125 outside of Southeast Asia and is actively preparing for further clinical development in other regions.
QTX153
QTX153 is a non-hydroxamic oral HDAC6 inhibitor for neurological disorders and obesity.
QTX153 is a highly selective and potent HDAC6 inhibitor developed by Quimatryx. It is specifically optimized for oral administration and designed to cross the blood–brain barrier, enabling direct modulation of epigenetic targets within the central nervous system.
QTX153 is developed for the treatment of neurological diseases such as Rett syndrome, Charcot-Marie-Tooth disease, and amyotrophic lateral sclerosis (ALS).
In addition, thanks to its brain penetration and strong HDAC6 selectivity, QTX153 is also being developed as a novel therapy for obesity, acting on hypothalamic circuits involved in appetite regulation and leptin resistance. This central mechanism complements current metabolic therapies and opens the door to more effective and sustainable combination treatments.
THE MOLECULE – QTX153
➟High selectivity for HDAC6 with minimal off-target effects.
➟High oral bioavailability.
➟Effective brain penetration demonstrated in preclinical models.
➟Favorable pharmacokinetic profile supporting systemic and CNS exposure.
➟Safety profile in a 3-week tolerability study in mice and MTD study in rats.
HDAC6 INHIBITION IN OBESITY
HDAC6 also plays a key role in central metabolic regulation, modulating hypothalamic circuits that control appetite, leptin sensitivity, and energy balance.
Its hyperactivation contributes to leptin resistance and disrupted signaling between adipose tissue and the brain, promoting increased food intake, reduced energy expenditure, and difficulty maintaining a healthy body weight.
Selective inhibition of HDAC6 in the central nervous system offers a new therapeutic avenue for obesity, with the potential to restore leptin sensitivity, improve appetite control, and promote more physiological and sustainable weight loss, particularly as a complement to current metabolic therapies.
PRECLINICAL RESULTS IN OBESITY
➟ Diet-induced obesity (DIO) models: central HDAC6 inhibition produced significant reductions in body weight and caloric intake.
➟ Leptin sensitization: restoration of hypothalamic leptin signaling, a key mechanism impaired in obesity.
➟ Preservation of lean mass: weight loss occurred primarily at the expense of adipose tissue, with maintenance of muscle mass.
➟ Improved energy balance: increased energy expenditure and normalization of central metabolic activity.
HDAC6 INHIBITION IN NEUROLOGICAL DISEASES
HDAC6 plays a crucial role in CNS by regulating axonal transport, protein degradation, and inflammatory responses.
Its hyperactivation disrupts neuronal homeostasis and contributes to the pathogenesis of neurodegenerative diseases.
Selective HDAC6 inhibition represents a promising strategy to restore neuronal function, reduce inflammation, and slow disease progression.
PRECLINICAL RESULTS IN NEUROLOGICAL DISEASES
QTX153 has demonstrated robust efficacy across multiple neurological disease models:
➟ Rett syndrome: improved survival and phenotypic symptoms in male and female mouse models, restoring dendritic branching and synaptic spine density.
➟ Charcot-Marie-Tooth disease (CMT): corrected neuromuscular deficits in a CMT2 mouse model.
➟ Amyotrophic lateral sclerosis (ALS): increased survival and improved motor activity in a Drosophila melanogaster model.